Nataliya Mar
Overview
Explore the profile of Nataliya Mar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
330
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Yazdanpanah O, Lee F, Houshyar R, Nourbakhsh M, Mar N
SAGE Open Med Case Rep
. 2024 Jan;
12:2050313X231223469.
PMID: 38187811
Gastroesophageal junction hepatoid adenocarcinoma is a rare form of gastroesophageal cancer. We present a case of a 38-year-old man with no significant medical history who was diagnosed with gastroesophageal junction...
12.
Mar N, Dwabe S, Baranda M, Zarrabi K, Eturi A, Gulati S, et al.
Clin Genitourin Cancer
. 2023 Dec;
22(2):217-223.
PMID: 38087703
Introduction: Despite the introduction of various novel therapies for management of metastatic castrate resistant prostate cancer (mCRPC) in recent decades, available treatment options are finite and remain limited. Multiple historical...
13.
Grant C, de Kouchkovsky D, Kalebasty A, Mar N
J Oncol Pharm Pract
. 2023 Jul;
29(7):1789-1792.
PMID: 37401244
Introduction: Enfortumab vedotin is an antibody drug conjugate approved for management of pretreated locally advanced or metastatic urothelial carcinoma, which is associated with a rare risk of drug extravasation and...
14.
ODonnell P, Milowsky M, Petrylak D, Hoimes C, Flaig T, Mar N, et al.
J Clin Oncol
. 2023 Jun;
41(25):4107-4117.
PMID: 37369081
Purpose: Patients with locally advanced or metastatic urothelial cancer (la/mUC) who are ineligible for cisplatin-based therapy have limited first-line (1L) treatment options and significant need for improved therapies. Enfortumab vedotin...
15.
Mar N, Zakharia Y, Falcon A, Morales-Barrera R, Mellado B, Duran I, et al.
Cancers (Basel)
. 2023 Jun;
15(11).
PMID: 37296940
Ibrutinib is a first-in-class Bruton's tyrosine kinase inhibitor approved for the treatment of various B-cell malignancies and chronic graft-versus-host disease. We evaluated the safety and efficacy of ibrutinib, alone or...
16.
Kaakour D, Seyedin S, Houshyar R, Mar N
Biomedicines
. 2022 Dec;
10(12).
PMID: 36551787
The prognosis for patients with penile squamous cell carcinoma metastatic to regional lymph nodes or distant sites remains poor with limited treatment options, especially after the failure of first-line chemotherapy....
17.
Benjamin D, Mar N, Kalebasty A
Clin Med Insights Oncol
. 2022 Oct;
16:11795549221126252.
PMID: 36186672
The treatment landscape of metastatic urothelial cancer (mUC) remained unchanged for over 30 years until the approval of immune checkpoint inhibitors (ICIs) in 2016. Since then, several ICIs have been...
18.
Mar N, Uchio E, Kalebasty A
Cancer Treat Res Commun
. 2022 Apr;
31:100564.
PMID: 35472699
Checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 have revolutionized oncologic care delivery, including clinical management of genitourinary malignancies. Despite significant associated improvement in patient outcomes, molecular heterogeneity of tumors, variable tumor...
19.
Baweja A, Mar N, Kalebasty A
World J Clin Oncol
. 2022 Feb;
13(1):62-70.
PMID: 35116233
Background: Late relapses of early-stage germ cell tumors are rare. Most patients (-85%) with stage I seminoma are cured by radical orchiectomy. The detection of late relapse is challenging given...
20.
Azizi A, Houshyar R, Mar N
J Oncol Pharm Pract
. 2022 Jan;
28(5):1226-1229.
PMID: 35043748
Introduction: Enfortumab vedotin is an antibody-drug conjugate used in patients with pretreated advanced urothelial carcinoma. Patients with human immunodeficiency virus were excluded from clinical trials conducted with this agent. Efficacy...